Jan 5, 2026 04:24AM Stoke Therapeutics (STOK) PT Raised to $36 at Canaccord Genuity

Dec 16, 2025 06:53AM Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright

Dec 5, 2025 09:01AM Stoke Therapeutics and Biogen present zorevunersen data at epilepsy meeting

Dec 1, 2025 07:31AM Stoke and Biogen to present zorevunersen data at epilepsy conference

Nov 17, 2025 07:30AM Stoke and Biogen publish data showing Dravet syndrome severity

Nov 4, 2025 05:57PM Stoke Therapeutics, Inc. (STOK) Misses Q3 EPS by 7c

Oct 13, 2025 01:34PM Stoke Therapeutics (STOK) PT Raised to $39 at BTIG

Oct 10, 2025 07:23AM Stoke Therapeutics (STOK) PT Raised to $35 at Needham

Oct 9, 2025 04:31PM Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome

Sep 2, 2025 07:03AM Biogen and Stoke present three-year zorevunersen data for Dravet syndrome

Sep 2, 2025 07:01AM Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet

Aug 25, 2025 07:00AM Stoke Therapeutics and Biogen to present zorevunersen data at epilepsy congress

Aug 18, 2025 05:11AM Stoke Therapeutics (STOK) PT Lowered to $28 at BTIG

Aug 12, 2025 04:04PM Stoke Therapeutics, Inc. (STOK) Tops Q2 EPS by 10c

Jul 18, 2025 02:02AM Jefferies Starts Stoke Therapeutics (STOK) at Buy

Jul 14, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)

Jul 9, 2025 04:04PM Stoke Therapeutics Inc. (STOK) Files $400M Mixed Shelf

May 15, 2025 06:48AM Stoke Therapeutics (STOK) PT Lowered to $35 at H.C. Wainwright

May 14, 2025 01:54AM Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 182c

Mar 20, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)

Mar 18, 2025 07:01AM Stoke Therapeutics, Inc. (STOK) Tops Q4 EPS by 37c

Mar 18, 2025 06:58AM Stoke Therapeutics (STOK) Announces CEO Transition

Feb 18, 2025 09:58AM BTIG Reiterates Buy Rating on Stoke Therapeutics (STOK)

Feb 18, 2025 08:03AM Biogen (BIIB) and Stoke Therapeutics (STOK) Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome

Jan 8, 2025 06:36AM Cantor Fitzgerald Reiterates Overweight Rating on Stoke Therapeutics (STOK)

Jan 7, 2025 07:02AM Stoke Therapeutics Inc. (STOK) Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen

Dec 5, 2024 07:00AM BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho

Dec 4, 2024 07:01AM Stoke Therapeutics Inc. (STOK) Receives FDA Breakthrough Therapy Designation for Zorevunersen

Nov 5, 2024 07:43AM Stoke Therapeutics, Inc. (STOK) Tops Q3 EPS by 7c

Oct 9, 2024 04:20PM Stoke Therapeutics Inc. (STOK) files mixed shelf

Sep 11, 2024 09:10AM TD Cowen Reiterates Buy Rating on Stoke Therapeutics (STOK)

Sep 11, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)

Sep 10, 2024 07:02AM Stoke Therapeutics (STOK) Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition

Sep 4, 2024 08:04AM Stoke Therapeutics Inc. (STOK) Appoints Eric Olson as Chief Business Officer

Jun 13, 2024 04:11PM Stoke Therapeutics Inc. (STOK) Files for 10.84M Share Offering by Selling Stockholders